重组人表皮生长因子治疗老年反复发作性口腔溃疡的临床疗效

摘要

目的 探讨重组人表皮生长因子治疗老年反复发作性口腔溃疡的临床疗效.方法 选取2013年1月～2015年6月宁波市奉化区中医医院收治的反复发作性口腔溃疡老年患者82 例,对照组41 例,常规西医治疗,研究组41 例,重组人表皮生长因子治疗,治疗前后采血测定免疫状况,对比临床疗效及不良反应,同时对患者行一年期随访.结果 研究组治疗有效率95.12％显著低于对照组治疗有效率为78.05％( P<.0.05);研究组治疗后3、6、12个月时复发率低于对照组复发率( P<.0.05);研究组治疗后CD3+及CD4+/CD8+、NK水平均高于对照组,CD8+水平低于对照组( P<.0.05);2组均无严重不良反应.结论 采用重组人表皮生长因子治疗口腔溃疡疗效显著,复发率低.%Objective To investigate the clinical efficacy of recombinant human epidermal growth factor in the treatment of recurrent oral ulcers in elderly patients.Methods 82 cases of elderly patients in our hospital in the treatment of recurrent oral ulcer were selected,41 cases in the control group,the conventional western medicine treatment,41 cases of the study group,recombinant human epidermal growth factor in treatment before and after treatment,blood determination of immune status,clinical efficacy and adverse reactions of comparison were performed at one-year follow-up.Results the effective rate of treatment group is lower than 78.05％of the effective rate of treatment group 95.12％,study group 3,6 and 12 months recurrence rate(4.88％,7.32％,7.32％)than in the control group the recurrence rate(19.51％,24.39％,29.27％),the study group after the treatment of CD3+ and CD4+/CD8+ and NK were higher than the control group,the CD8+ level is lower than the control group(P<0.05),the two groups had no serious adverse reaction.Conclusion recombinant human epidermal growth factor is effective in the treatment of oral ulcer.